Aerovate Therapeutics Inc
AVTE2.680USD
0.000
交易中 （美东）报价延迟15分钟
77.68M总市值
亏损市盈率 TTM
关于 Aerovate Therapeutics Inc 公司
Aerovate Therapeutics Inc. 是一家临床阶段的生物制药公司。该公司专注于开发能够显著改善罕见心肺疾病患者生活的药物。其最初的重点是推进 AV-101，这是一种用于治疗肺动脉高压 (PAH) 的伊马替尼干粉吸入剂型，这是一种影响美国和欧洲约 70,000 人的毁灭性疾病。口服伊马替尼在 PAH 患者的主要终点、六分钟步行距离和多个次要血流动力学终点方面也表现出统计学上的显著改善。AV-101 使用干粉吸入器输送，旨在提供等于或高于口服剂量的肺部浓度，同时限制药物的全身水平。PAH 是一种医疗需求尚未得到满足的罕见病，其特征是将血液从心脏右侧输送到肺部的血管压力较高。
Aerovate Therapeutics Inc简介
公司代码AVTE
公司名称Aerovate Therapeutics Inc
上市日期- -
CEOMr. Timothy P. Noyes
员工数量- -
证券类型Ordinary Share
年结日- -
公司地址930 Winter Street
城市WALTHAM
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02451
电话16174432400
网址https://www.aerovatetx.com/
公司代码AVTE
上市日期- -
CEOMr. Timothy P. Noyes
Aerovate Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
Mr. Mark Iwicki
Mr. Mark Iwicki
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Dr. Joshua Resnick, M.D.
Dr. Joshua Resnick, M.D.
Independent Director
Independent Director
--
--
Mrs. Susan Fischer
Mrs. Susan Fischer
Executive Vice President - Development Operations
Executive Vice President - Development Operations
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Benjamin T. Dake, Ph.D.
Dr. Benjamin T. Dake, Ph.D.
President, Chief Operating Officer, Secretary
President, Chief Operating Officer, Secretary
505.00
+9.31%
Mr. Bradford D. (Brad) Dahms
Mr. Bradford D. (Brad) Dahms
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Mr. Habib Joseph Dable
Mr. Habib Joseph Dable
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Marinus Verwijs, Ph.D.
Dr. Marinus Verwijs, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
Dr. Ralph Niven, Ph.D.
Dr. Ralph Niven, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Allison Dorval, CPA
Ms. Allison Dorval, CPA
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 9月30日 周二
更新时间: 9月30日 周二
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.52%
Fairmount Funds Management LLC
13.96%
VR Adviser, LLC
9.87%
RA Capital Management, LP
9.85%
Deep Track Capital LP
7.69%
其他
44.11%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
14.52%
Fairmount Funds Management LLC
13.96%
VR Adviser, LLC
9.87%
RA Capital Management, LP
9.85%
Deep Track Capital LP
7.69%
其他
44.11%
股东类型
持股股东
占比
Hedge Fund
31.30%
Venture Capital
28.35%
Investment Advisor
26.80%
Investment Advisor/Hedge Fund
12.93%
Private Equity
7.06%
Research Firm
0.91%
Bank and Trust
0.12%
Individual Investor
0.06%
Insurance Company
0.04%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
217
31.60M
97.02%
+20.45M
2025Q2
214
13.42M
41.64%
+12.20M
2025Q1
214
927.53K
47.43%
-347.78K
2024Q4
217
30.84M
106.81%
-7.10M
2024Q3
214
28.32M
98.10%
-8.69M
2024Q2
210
27.84M
96.65%
-3.71M
2024Q1
181
29.16M
104.58%
-1.74M
2023Q4
173
28.88M
104.29%
-1.94M
2023Q3
168
28.55M
103.17%
-3.10M
2023Q2
169
28.55M
103.46%
+487.13K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
4.74M
14.52%
+232.00
+0.00%
Jun 30, 2025
Fairmount Funds Management LLC
3.22M
9.87%
--
--
Jun 30, 2025
VR Adviser, LLC
3.22M
9.87%
+3.13M
+3399.98%
Jun 30, 2025
RA Capital Management, LP
1.06M
3.26%
-262.63K
-19.82%
Jun 30, 2025
Deep Track Capital LP
2.51M
7.69%
+2.43M
+3053.93%
Jun 30, 2025
The Vanguard Group, Inc.
1.81M
5.54%
+1.78M
+5829.22%
Jun 30, 2025
Frazier Life Sciences Management, L.P.
1.77M
5.43%
+1.73M
+4526.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.56M
4.78%
+1.54M
+6191.66%
Jun 30, 2025
Versant Ventures
1.53M
4.68%
+1.53M
--
Jun 30, 2025
RTW Investments L.P.
1.45M
4.44%
+1.45M
--
Jun 30, 2025
查看更多
持股ETF
更新时间: 8 小时前
更新时间: 8 小时前
机构名称
占比
iShares Micro-Cap ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ALPS Medical Breakthroughs ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
查看更多
iShares Micro-Cap ETF
占比0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Proshares Ultra Russell 2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ALPS Medical Breakthroughs ETF
占比0%
Virtus LifeSci Biotech Clinical Trials ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
